126145-99-1

Usage

Uses

Used in Medicinal Chemistry:
4-(4-BROMO-BENZENESULFONYLAMINO)-BENZOIC ACID is used as a building block for the synthesis of various pharmaceutical agents. Its unique structure allows it to be a valuable component in the development of new drugs with potential therapeutic applications.
Used in Organic Synthesis:
4-(4-BROMO-BENZENESULFONYLAMINO)-BENZOIC ACID is used as a reagent in organic synthesis, enabling the creation of a wide range of chemical compounds for various purposes, including the development of new materials and the improvement of existing ones.
Used in Chemical Reactions:
4-(4-BROMO-BENZENESULFONYLAMINO)-BENZOIC ACID is used as a reagent in chemical reactions, facilitating the formation of new compounds and aiding in the advancement of chemical research and development.
Used in Pharmaceutical Research:
4-(4-BROMO-BENZENESULFONYLAMINO)-BENZOIC ACID is used as a compound of interest in pharmaceutical research, where its potential to interact with biological targets and exhibit pharmacological activity is explored for the development of new therapeutic agents.

InChI:InChI=1/C13H10BrNO4S/c14-10-3-7-12(8-4-10)20(18,19)15-11-5-1-9(2-6-11)13(16)17/h1-8,15H,(H,16,17)/p-1

Upstream product

• 150-13-0 4-amino-benzoic acid 
• 98-58-8 4-bromobenzenesulfonyl chloride 
• 59256-26-7 methyl 4-{[(4-bromophenyl)sulfonyl]amino}benzoate 
• 619-45-4 4-methoxycarbonyl aniline 

Downstream Products

• 6336-70-5 4-(4-aminobenzenesulfonylamino)benzoic acid 
• 1602529-66-7 C₁₃H₉BrClNO₃S 

Relevant academic research and scientific papers

Bio-potent sulfonamides

Some 4-(substituted phenylsulfonamido)benzoic acids have been synthesized by fly-ash:H3PO3 nano catalyst catalyzed condensation of substituted benzenesulfonyl chlorides and 4-aminobenzoic acid in ultrasound irradiation conditions. The yields of the sulfonamides are more than 90%. The synthesized 4-(substituted phenylsulfonamido) benzoic acid derivatives were characterized by their physical constants, analytical and spectroscopic data. Antimicrobial activities of all sulfonamides were measured by Bauer-Kirby disc diffusion method.

Aminobenzoic acid derivatives as antioxidants and cholinesterase inhibitors; synthesis, biological evaluation and molecular docking studies

Cholinesterase namely, acetyl- and butyrylcholinesterase (AChE and BChE, respectively), has been recognized as a primary class of enzyme that hydrolyzes the acetylcholine (ACh) neurotransmitter in synaptic junctions. Diminished levels of the neurotransmitter in synaptic junction lead to Alzheimerís disease (AD). Inhibition of cholinesterase is thus, an attractive strategy for AD treatment. The study includes the synthesis and characterization of a series of 2-, 3- and 4-aminobenzoic acid derivatives (1a?5c), their biological screening against cholinesterase enzyme and molecular docking study to demonstrate putative binding modes. Antioxidant potential of the synthesized series was also determined. The cholinesterase enzyme inhibition assay showed that compound 5b has the highest inhibition potential against acetylcholinesterase with an IC50 value of 1.66 ± 0.03 μM while in case of butyrylcholinesterase, compound 2c has the highest inhibitory potential with an IC50 value of 2.67 ± 0.05 μM. Molecular docking studies supports the results of enzyme inhibition potential with binding energy value ?G = -9.54 Kcal mol-1 for compound 5b in case for acetylcholinesterase while for butyrylcholinesterase, ?G = -5.53 Kcal mol-1 was obtained for compound 2c. The synthesized series of compounds also shows mild to moderate antioxidant potential. The benzoyl- containing compounds shows better antioxidant activity as compared to other derivatives of the synthesized series. Based on the molecular docking studies and enzyme inhibition potential, the synthesized series of compounds can be regarded as potent cholinesterase inhibitors and can be used for designing and synthesizing more potent drugs for Alzheimerís disease and neurodegenerative diseases.

Design, synthesis and biological evaluation of novel non-peptide boronic acid derivatives as proteasome inhibitors

A series of novel non-peptide boronic acid derivatives were designed and synthesized via rational drug design principles. All target compounds were screened for the proteasome inhibitory activities in vitro. Selected compounds (6a and 7j) were evaluated f